Development of small molecule inhibitors/agonists targeting STING for disease

Biomed Pharmacother. 2020 Dec:132:110945. doi: 10.1016/j.biopha.2020.110945. Epub 2020 Nov 1.

Abstract

Cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) -stimulator of interferon genes (STING) signaling pathway is the primary immune response pathway in the cytoplasm. Pharmacological regulation of the STING pathway has good characteristics in both structure and function, which plays a significant role in the immunotherapy of autoimmune diseases, autoinflammatory diseases, and cancer. In this review, we summarized the activation of STING signaling pathway, the STING-related diseases, the development principle and the latest progress of inhibitors and agonists targeting STING. Our review demonstrates that STING signal pathway is a promising drug target, providing effective clues and correct guidance for the discovery of novel small molecule inhibitors/agonists that targeted STING for cancer, autoimmune, and inflammatory diseases.

Keywords: Disease; Innate immune response; Small molecule agonists; Small molecule inhibitors; Stimulator of interferon genes.

Publication types

  • Review

MeSH terms

  • Animals
  • Autoimmune Diseases / drug therapy
  • Autoimmune Diseases / metabolism
  • Drug Delivery Systems / methods*
  • Drug Delivery Systems / trends
  • Drug Development / methods*
  • Drug Development / trends
  • Humans
  • Immunotherapy / methods
  • Immunotherapy / trends
  • Membrane Proteins / agonists*
  • Membrane Proteins / antagonists & inhibitors*
  • Membrane Proteins / metabolism
  • Neoplasms / drug therapy
  • Signal Transduction / drug effects
  • Signal Transduction / physiology

Substances

  • Membrane Proteins
  • STING1 protein, human